India · Delayed Price · Currency is INR Gufic Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 delivered record revenue and profitability, driven by Indore facility ramp-up, strong domestic growth in women's health and aesthetics, and a strategic shift in international business. Margins and revenue are expected to improve further in FY 2027, with stable debt and no major CapEx planned.
-
Q3 FY26 saw flat sequential revenue and EBITDA, with PAT slightly up. Domestic branded business grew modestly, while exports and toxin segments outperformed. Indore plant ramp-up and regulatory progress set the stage for 15-20% growth and margin expansion in FY27.
-
Revenue and margins improved sequentially, driven by Indore facility ramp-up and higher international business mix. Domestic infertility and botulinum toxin divisions showed strong growth, while CMO business is set to recover as more clients transition to Indore.
-
Revenue grew 10% sequentially to INR 226.96 crore, driven by the Indore facility ramp-up and strong export momentum. EBITDA and profit margins improved, with further gains expected as capacity utilization and exports increase. Indore is set to become a margin accretive asset from FY 2027.
Fiscal Year 2025
-
Revenue and EBITDA grew YoY in Q4, but margins declined due to Indore facility fixed costs. Indore is expected to reach EBITDA break-even in FY26 and full profitability by FY27, with international business targeted to reach 25% of revenue in 2-3 years.
-
Revenue and margins remained stable despite price erosion in key molecules, with new product launches and the Indore facility ramp-up expected to drive future growth. Margin pressure is anticipated in the near term due to Indore-related costs, but improvement is expected post-2026 as utilization increases.
-
Revenue and profit margins remained stable despite a slight YoY decline, as the Indore facility began phased production with minimal FY25 impact. Strategic business units expanded, and international growth was supported by new approvals and a UK NHS tender.
-
Q1 FY25 saw modest revenue and profit growth, with stable margins amid capacity constraints. Indore facility validation is nearly complete, with commercial production set to drive scale, margin expansion, and export growth. Debt is stable, with deleveraging planned as new capacity ramps up.